Abstract
Several quinolones have been shown to have antichlamydial activity in vitro and in vivo. We evaluated the effects of the quinolone CI-960 (Parke-Davis) on primary or repeated chlamydial infection in the monkey salpinx pocket model. The antichlamydial effect was evaluated in the tissues, and we tested for the presence of the organism by culture, immunocytochemical stains, in situ hybridization, and histopathology. An intravenous dosage of 5 mg/kg of body weight produced therapeutic concentrations in plasma (blood sera and pocket fluids) of at least 0.25 microgram/ml at 2 h posttreatment. In monkeys with primary infections, treatment was started 2 days after inoculation and was continued for 7 days. After CI-960 treatment, all animals became culture negative. One of two control animals was culture positive through day 10 postinoculation. In monkeys with repeated infections five inoculations were given within 2 weeks. A 7-day intravenous treatment was started on day 2 postinoculation following the last inoculation. Isolation of Chlamydia trachomatis prior to treatment was positive intermittently for all monkeys. After treatment, isolation of C. trachomatis was negative for all monkeys. In monkeys with both primary and repeated infections, no significant differences were noted in the inflammatory responses in the tissues of treated and untreated animals. All tissues tested were positive by immunoperoxidase staining and/or in situ hybridization. After CI-960 therapy, C. trachomatis organisms were no longer recoverable by cell culture. The persistent finding of chlamydial DNA throughout the observation periods following drug therapy may indicate the presence of dead organisms or viable organisms in an unculturable state.
Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Børsum T., Dannevig L., Størvold G., Melby K. Chlamydia trachomatis: in vitro susceptibility of genital and ocular isolates to some quinolones, amoxicillin and azithromycin. Chemotherapy. 1990;36(6):407–415. doi: 10.1159/000238797. [DOI] [PubMed] [Google Scholar]
- Cates W., Jr, Wasserheit J. N. Genital chlamydial infections: epidemiology and reproductive sequelae. Am J Obstet Gynecol. 1991 Jun;164(6 Pt 2):1771–1781. doi: 10.1016/0002-9378(91)90559-a. [DOI] [PubMed] [Google Scholar]
- Fransen L., Avonts D., Piot P. Treatment of genital chlamydial infection with ofloxacin. Infection. 1986;14 (Suppl 4):S318–S320. doi: 10.1007/BF01661307. [DOI] [PubMed] [Google Scholar]
- Palmer L., Falkow S. A common plasmid of Chlamydia trachomatis. Plasmid. 1986 Jul;16(1):52–62. doi: 10.1016/0147-619x(86)90079-x. [DOI] [PubMed] [Google Scholar]
- Patton D. L., Kuo C. C. Histopathology of Chlamydia trachomatis salpingitis after primary and repeated reinfections in the monkey subcutaneous pocket model. J Reprod Fertil. 1989 Mar;85(2):647–656. doi: 10.1530/jrf.0.0850647. [DOI] [PubMed] [Google Scholar]
- Patton D. L., Kuo C. C., Wang S. P., Brenner R. M., Sternfeld M. D., Morse S. A., Barnes R. C. Chlamydial infection of subcutaneous fimbrial transplants in cynomolgus and rhesus monkeys. J Infect Dis. 1987 Feb;155(2):229–235. doi: 10.1093/infdis/155.2.229. [DOI] [PubMed] [Google Scholar]
- Slaney L., Chubb H., Ronald A., Brunham R. In-vitro activity of azithromycin, erythromycin, ciprofloxacin and norfloxacin against Neisseria gonorrhoeae, Haemophilus ducreyi, and Chlamydia trachomatis. J Antimicrob Chemother. 1990 Jan;25 (Suppl A):1–5. doi: 10.1093/jac/25.suppl_a.1. [DOI] [PubMed] [Google Scholar]
- Stamm W. E., Suchland R. Antimicrobial activity of U-70138F (paldimycin), roxithromycin (RU 965), and ofloxacin (ORF 18489) against Chlamydia trachomatis in cell culture. Antimicrob Agents Chemother. 1986 Nov;30(5):806–807. doi: 10.1128/aac.30.5.806. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wang S. P., Grayston J. T., Alexander E. R., Holmes K. K. Simplified microimmunofluorescence test with trachoma-lymphogranuloma venereum (Chlamydia trachomatis) antigens for use as a screening test for antibody. J Clin Microbiol. 1975 Mar;1(3):250–255. doi: 10.1128/jcm.1.3.250-255.1975. [DOI] [PMC free article] [PubMed] [Google Scholar]